Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.
Clinical trial research on the treatment of sub-cutaneous (subQ) migaldendranib (MGB), sponsored by Ashvattha Therapeutics, has announced interim results from an ongoing Phase II study… Read More »Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.